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Abstract
Objective: Post-mortem brain samples from 15 deceased patients whose death was heroin related, were analyzed 
to determine 6-monoacetyl-morphine (6-MAM) concentrations. The samples belonged to people died between 2008 
and 2014. The first eight samples were also analyzed in 2012 to determine only morphine and codeine levels.
Method: A GC/MS method was studied in order to enhance sensitivity, thus helping the determination of 6-MAM 
whose detection is in most cases difficult because of the complexity of the biological matrix. The analytical method 
was validated using deuterated internal standards (IS-D3, morphine-D3 and codeine-D3) and it showed adequate 
specificity, linearity, LOD, LOQ precision and accuracy for the determination of the analyte of interest.
Results: 6-MAM was evidenced only in the more recent samples, thus pointing out its low stability. Its concentration 
ranged from 15.6 to 28.9 ng/g. Morphine and codeine was also determined and a comparison was carried out 
between the blood and the brain levels of the three analytes. Moreover a parallel was established between the 
concentrations of morphine and codeine found in the brain in 2012 and 2015.
Conclusion: 6-MAM determination in the brain is particularly important when discriminating between morphine 
assumption and heroin abuse. In fact in the cases in which it is not detectable in the blood it can be present in the 
brain. It was noticed that the concentrations of morphine found in the brain in 2015 are higher respect to the levels 
of 2012; a possible explanation could be that 6-MAM originally present in the brain has hydrolyzed to morphine, thus 
increasing its levels.
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Introduction
The concentration of drugs of abuse, which are susceptible to rapid 
chemical and metabolic hydrolysis, in blood does not always reflects 
drug concentration at the site of action [1], especially in the case of 
death for heroin overdose, because post-mortem redistribution or drug 
instability can result in misleading variations of plasmatic drug levels 
[2]. In fact the detection of heroin in the biological fluids of consumers 
is difficult due to its short half-life (2–6 minutes after intravenous 
injection) [3]. In the body, it is rapidly hydrolyzed to 6-monoacetyl-
morphine (6-MAM), which in turn is converted into morphine. 
Subsequently, morphine is conjugated with glucuronic acid to give mainly 
morphine-3-β-d-glucuronide and morphine-6-β-d-glucuronide [3,4]. 
Direct measurements of heroin metabolites concentrations in the brain are 
useful in post-mortem forensic toxicology to substantiate fatal overdoses 
[5] because drugs of abuse exert their effects via the central nervous system, 
so that it can be assumed that the encephalic concentration of these drugs, 
measured in post-mortem specimens, is close or equal to their peri-
mortem concentration at their site of action [6]. Moreover brain samples 
show several advantages respect to other specimens because brain is an 
isolate compartment, endowed with lower metabolic activity, resulting in 
slower decomposition and delayed process of putrefaction [7,8]. On the 
other hand the brain represents a complex matrix and analysis can be 
complicated.
In our laboratory, post-mortem samples are routinely subjected 
to a systematic toxicological analysis (STA) in order to highlight the 
presence of unknown exogenous compounds (e.g., drugs of abuse, 
alcohol) that may have played a role in the mechanism of death [9].
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In cases in which STA suggests the presence of morphine and 
codeine, brain specimens are also typically analyzed [4]. In a previous 
study [10], we developed a gas chromatography/mass spectrometry 
(GC/MS) method to investigate the brain distribution patterns of 
morphine and codeine, which was then, applied to the determination of 
their levels in nuclei specimens from 14 fatal cases of suspected heroin 
overdose. The results of this analysis were subsequently compared 
to metabolite levels in the blood obtained from the systematic 
toxicological analysis (STA) [11]. In this work we focused our attention 
on the detection of 6-MAM, whose presence is extremely important to 
discriminate between heroin abuse and therapeutic use of morphine 
[12-15]. Analyses were performed in fifteen brain samples from 
heroin fatalities belonging to a period of time between 2008 and 2014. 
The first eight samples were also analyzed in 2012 [11] to determine 
morphine and codeine levels. The other seven cases were analyzed for 
the first time. To this end a modified GC/MS method was studied, 
applied and validated in order to enhance sensitivity, thus helping the 
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Standards solutions of 6-MAM (0.1 µg/mL), morphine (0.1 µg/
mL) and codeine (0.1 µg/mL) were prepared in methanol as well as 
the internal standard solution (IS-D3; 0.5 µg/mL of morphine-D3 and 
0.5 µg/mL of codeine-D3). Every day working standard samples (WSS) 
containing 20 ngtot of 6-MAM, 100 ngtot of morphine and 100 ngtot of 
codeine were prepared in methanol. 
Brain tissue sample preparation and deproteinization
Each sample was homogenized by blending or ball milling 
(depending on the quantity of the material available) and deproteinized 
via an ultrasonic bath using the following protocol: 500 mg brain 
tissue and 100 µl IS-D3 were diluted with 4 ml water and 2 ml pH 
9 buffer solution. The resulting mixture was sonicated for 15 min at 
room temperature. After centrifugation (4000 rpm, 5 min), the clear 
supernatant was separated and extracted via SPE.
Extraction procedure
Homogenized and deproteinized encephalic samples were extracted 
using Bond Elut-LRC Certify solid phase extraction cartridges (Varian, 
Palo Alto, CA, US) with a Varian vacuum manifold (Varian, CA, USA). 
Cartridges were first conditioned with 2 ml methanol and 2 ml pH 9 
buffer solutions. The supernatants resulting from the centrifugation 
were loaded on to the cartridges and permitted to absorb through 
gravity. The cartridges were then washed with 2 ml water, 3 ml of 1 M 
hydrochloric acid and 0.5 ml methanol. The analytes were subsequently 
eluted with 2 × 1 ml elution solvent (dichloromethane/isopropyl 
alcohol/ammonium hydroxide, 8/2/0.2, v/v/v).
Chromatography
The extracts were evaporated to dryness under a stream of nitrogen at 
40°C and derivatized with a mixture of BSTFA (N,O-bis(trimethylsilyl) 
trifluoroacetamide) 99% and TMCS (trimethylchlorosilane) 1% 
(50 µl) at 70°C for 30 min. GC/MS analysis was performed on a GC 
6890 Plus with a mass selective detector and 6890 autosampler. Data 
were analyzed with MSD ChemStation D.03.00 software (Agilent 
Technologies). Chromatographic separation was carried out on a RXI-
5silMS (G59) capillary column (30 m × 0.25 mm I.D., thickness 0.25 
µm; Restek Bellefonte PA, US). 
The GC/MS system was operated under the following conditions: 
injection temperature: 280°C (splitless mode; 0.25 min splitless 
determination of 6-MAM using deuterated internal standards (IS-D3, 
morphine-D3 and codeine-D3).
Experimental
Cases
Post-mortem samples, which were supplied by the Institute of 
Legal Medicine and Assurance at the University of Palermo, were 
collected from 15 deceased patients (Table 1). The subjects were mainly 
men aged between 23 and 56 years (mean 39 years), and circumstantial 
evidence suggested that the deaths in each case were heroin related. 
Eight samples (cases 1-8) belonged to people died between 2008 and 
2011 and they were analyzed also in 2012 to establish morphine and 
codeine levels [11]. Seven samples belonged to people died between 
2012 and 2014 and they were analyzed for the first time. Nuclei was 
the brain area withdrawn in all cases as it is representative of the 
concentration of the analytes in all the brain [9]
All autopsies performed at the Institute of Legal Medicine and 
Assurance at the University of Palermo was reviewed, and the autopsy 
documentation, including the charts, final reports and circumstances 
surrounding each death, were recorded. 
Tissue samples from each organ were routinely collected from the 
subjects during the autopsy and stained with hematoxylin and eosin 
for histological assessment. During the overall examination of each 
subject, the cause of death could not be conclusively determined and 
toxicological analysis was subsequently used to determine it.
Chemicals, reagents and standards
6-MAM, Morphine, Codeine, Morphine-D3, Codeine-D3 (internal 
standards, IS-D3) was purchased from S.A.L.A.R.S. (Italy). Methanol 
and acetonitrile were obtained from Sigma–Aldrich (Germany). 
Sodium tetraborate/hydrochloric acid (pH 9) buffer solution and the 
mixture BSTFA (N,O-bis(trimethylsilyl) trifluoroacetamide) 99% 
and TMCS (trimethylchlorosilane) 1% were purchased from Fluka 
(Switzerland); dichloromethane and isopropyl alcohol were obtained 
from Prolabo (Italy). Ammonium sulfate was supplied by Carlo Erba 
(Italy), as well as glacial acetic acid. Water (18.2 MΩ·cm-1) was obtained 
using a Milli-Q purification system (Millipore, France). All reagents 
were of analytical grade and stored according to the manufacturers’ 
instructions.
Case Age Gender Year of death
Brain (ng/g) Blood (ng/mL)
6-MAM Mor Cod 6-MAM Mor Cod
1 23 M 2008 <LOD 175.2 23.5 <LOD 33 10
2 24 M 2009 <LOD 165.5 35.4 <LOD 315 73
3 42 M 2009 <LOD 525.5 83.7 <LOD 338 64
4 45 M 2009 <LOD 534.5 44.3 <LOD 688 150
5 36 M 2009 <LOD 149.4 20.6 <LOD 615 193
6 45 M 2009 <LOD 241.5 47.0 <LOD 228 25
7 42 M 2011 <LOD 158.4 23.7 <LOD 130 <LOD
8 35 M 2011 <LOD 132.5 17.7 <LOD 171 <LOD
9 40 F 2012 <LOD 157.4 < LOD <LOD 117 9.1
10 56 M 2013 15.6 273.0 23.3 6.1 265 19.8
11 38 M 2013 20.5 375.2 35.6 <LOD 475 28.8
12 48 M 2013 28.9 246.4 25.4 <LOD 441 29.1
13 35 M 2014 24.6 157.1 20.2 <LOD 192 14.6
14 43 M 2014 <LOD 147.7 10.0 <LOD 78 11.3
15 30 M 2014 20.9 928.6 138.0 <LOD 764 85
Table 1: Overview of the cases studied and concentration of 6-MAM, morphine (Mor) and codeine (Cod) in the brain (ng/g) and in the blood (ng/mL) from STA [11].
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time); interface transfer line: 280°C; ion source: 230°C; initial column 
temperature: 70°C. The temperature was subsequently increased to 
180°C at a rate of 40°C min-1, then to 300°C at a rate of 10°C min-1 and 
held at this temperature for 5 min. Helium was used as the carrier gas 
at a flow rate of 1.2 ml min-1. Time of analysis 21 min. MS analysis was 
performed in SCAN (50/550 m/z) and SIM mode with a quadrupole 
mass detector operated in electron ionization mode, with beam energy 
of 70 eV. The injection volume was 1 μl. The ions selected for SIM 
mode acquisition were 287, 340, 399 for 6-MAM-TMS; 401, 414, 429 
for morphine-2-TMS; 313, 343, 371 for codeine –TMS; 417, 432 for 
morphine - D3 –2 TMS and 347, 374 for codeine – D3 – TMS (in bold 
the quantifier ions).
Method validation
Specificity: Specificity was assessed by extracting control blank 
brain samples in each validation run. The lack of interfering peaks 
at the same analyte retention times was considered as an acceptable 
selectivity.
Linearity: The linearity of the response of GC/MS analysis was 
checked for 6-MAM, codeine and morphine by plotting drug/internal 
standard peak area ratios versus the total amount of drug in the 
standard solutions, in the interval 10-1000 ng. Linearity was assessed 
for each analyte in a specific range preparing WSS at a concentration 
of 10, 15, 20, 50, 100 ngtot for 6-MAM; 50, 100, 250, 500, 1000 ngtot for 
morphine; 10, 25, 50, 75, 100 ngtot for codeine. To each standard solution 
500 mg of blank brain were added, the mixtures were centrifuged, then 
4 mL of water, 2 mL of pH 9 buffers and 100 µL of IS-D3 were added. 
The samples were then sonicated for 15 min and extracted via SPE. 
Linearity equations were y=0.0092x+0.0551 (R2=0.9905) for 6-MAM; 
y=0.0072x+0.2869 (R2=0.9977) for morphine; y=0.0118x−0.0057 
(R2=0.9815) for codeine. Calibration curves showed good correlation 
coefficients for all the analytes over the whole range.
Limit of quantitation (LOQ) and limit of detection (LOD): LOD 
and LOQ were evaluated analyzing a series of decreasing concentrations 
of drug-fortified homogenized brain samples. LOD was determined to 
be the lowest analyte concentration with an S/N ratio of at least 3 and 
resulted 5 ng for 6-MAM, 10 ng for morphine and 5 ng for codeine. 
LOQ was defined as the lowest concentration with an S/N ratio of at 
least 10 at which the values of accuracy and precision had a coefficient 
of variation below 15%. The LOQ was 10 ng for 6-MAM and codeine 
and 25 ng for morphine; it was calculated by analyzing standard 
solutions of 6-MAM (10 ngtot), morphine (25 ngtot) and codeine (10 
ngtot) during three days.
Accuracy: Accuracy was expressed as the recovery (%REC) 
evaluated by analyzing in triplicate five standard solutions for each 
analyte. In particular 10, 15, 20, 50, 100 ngtot for 6-MAM; 50, 100, 250, 
500, 1000 ngtot for morphine and 10, 25, 50, 75, 100 ngtot for codeine.
%REC was calculated according to: %REC= [Aanalyte/(AIS•RRmed•Ct)] 
× 100. Where Ct is the total amount of analyte in the standard solution 
and RRmedium is defined as follows.
The quantification of the three drugs was based on the response 
factor RR, defined as: RR= (Aanalyte/AIS)/Ct. Where Aanalyte and A IS are 
respectively the peak area of the analyte and the peak area of the IS 
and Ct is the analyte concentration in the working standard solution 
expressed as total ng of analyte. The response factor was calculated for 
all the working standard solutions described above and the averaged 
RRmedium was considered for the estimation of drugs concentration in 
brain specimens. Accuracy ranged from 70.5 to 120.5% (mean 100.0%) 
for 6-MAM; from 84.7 to 112.4% for morphine (mean 100.2%); from 
70.9 to 123.8% (mean 100.2%) for codeine.
Precision: The same standard solutions were analyzed in triplicate 
during three different days in order to evaluate the precision of the 
method. The RR value was calculated for every standard solution as 
well as the medium response ratios (RRmedium). Precision was expressed 
as %CV. The method showed adequate precision for all the analytes, 
%CV being 20.4% for 6-MAM, 12.2% for morphine and 19.1% for 
codeine.
Results and Discussion
In order to evaluate the distribution of morphine and codeine in 
the brain, in a previous study [11] a GC/MS method was applied to 
the determination of morphine and codeine levels in nuclei specimens 
from fourteen fatal cases of suspected heroin overdose. In this work, 
we focused our attention on the detection of 6-MAM in eight cases 
considered in the previous paper, of which a sufficient quantity of 
brain tissue was still available (cases 1-8). In these samples also the 
levels of morphine and codeine were evaluated. Moreover we analyzed 
other seven samples from heroin fatalities belonging to a period 
of time between 2012 and 2014 (cases 9-15). To this end we studied 
and validated an analytical method suitable to this purpose, using 
deuterated internal standards in order to enhance sensitivity (Figure 1). 
The results obtained from the analysis of the brain samples and a 
comparison with the blood levels obtained from STA [11] is reported 
in Table 1. 
With regards to the brain tissue samples, a wide distribution of 
both the concentration of morphine and codeine was noted, which is 
in agreement with the literature [15]. 
Even in the blood a high variability was found with regards to 
the morphine and codeine levels among the fifteen blood samples. 
As reported in our previous study [11] no relationship between the 
levels of the two analytes in each individual sample was found, as it is 
reasonable, being the concentration of codeine linked to the impurities 
found in “street heroin” (acetyl-codeine). 
As stated before particular attention was devoted to the detection 
of 6-MAM. From the table it is evident that this analyte was evidenced 
only the more recent brain samples (Figure 2), probably because it 
undergoes degradation in the brain tissue. In the blood 6-MAM was 
detected only in one case. The fact that sometimes 6-MAM is detected 
in the brain and not in the blood is particularly important. This means 
that when it is not present in the blood, it is mandatory to carry out the 
determination in the brain tissue before excluding its presence. 
In the cases in which analyses of morphine and codeine were 
carried out either in 2012 or in 2015, we did a comparison between 
the concentrations of the two analytes (Figure 3). It is possible to note 
that the trend of the analyte concentrations was comparable, even if 
the analytical method was different and a period of time of three years 
has elapsed between the two determinations. In the case of morphine, 
we noticed that the levels determined in 2015 are in some cases higher 
than those of 2012. This could be due to the hydrolysis of 6-MAM, 
which was not detected in these samples. To confirm this hypothesis, 
it could be interesting to analyze cases 9-15 after a few months to see if 
6-MAM is still present or it has hydrolyzed to morphine.
Conclusion
The determination of 6-MAM in the brain is particularly important 
because it allows the discrimination between heroin assumption and 
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Figure 1: SIM chromatogram of case n. 10.
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Figure 2: Comparison between the levels of 6-MAM, morphine and 
codeine in the brain.
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Figure 3: Comparison between the levels (ng/g) of morphine and codeine 
determined in 2012 and 2015 in the brain.
morphine therapeutic use. On the other hand its determination in 
brain tissue is particularly difficult because of its low concentration 
and stability. To this end we optimized and validated an analytical 
method suitable to this purpose, using deuterated IS for quantitative 
analysis. Together with 6-MAM we carried out the determination 
of morphine and codeine in the brain and in the blood to compare 
their levels and try to establish the distribution of heroin metabolites 
in different biological matrices. A high variability was found for 
morphine and codeine, while 6-MAM was detected only in the more 
recent samples confirming its instability in the brain. Eight samples of 
fifteen were analyzed in 2012 and 2015. The trend of the concentrations 
of the analytes was confirmed but the morphine levels found in 2015 
were higher than those of 2102. This could be due to the hydrolysis 
of 6-MAM to morphine. Furthermore in some cases 6-MAM is not 
detectable in the blood but it is present in the brain, thus highlighting 
the importance of the analysis of this tissue.
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